CLINICAL TRIALS PROFILE FOR MS CONTIN

All Clinical Trials for MS CONTIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003687 ↗	Treatment for Chronic Pain in Patients With Advanced Cancer	Completed	NCIC Clinical Trials Group	Phase 3	1998-06-11	RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain. PURPOSE: Randomized phase III trial to compare the effectiveness of different morphine formulations with or without dextromethorphan in treating chronic pain in patients who have advanced cancer.
NCT00009672 ↗	Pain Treatment for Sciatica	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	2001-01-30	This study will test the effectiveness of two drugs-nortriptyline and MS Contin (a type of morphine)-to treat pain caused by lumbar radiculopathy, or sciatica. Sciatica results from damage to the lumbar nerve roots, typically causing back pain and sharp, shooting pain down one or both legs. Although sciatica is common, there are no good treatments for it. Tricyclic antidepressants, such as nortriptyline, and opioids, such as morphine, have been effective in treating other kinds of pain from nerve damage. Patients between 18 and 65 years of age who have had sciatica pain daily for at least 3 months may be eligible for this study. Participants will provide a medical history and occupational and other social information. They will undergo a neurological examination, routine blood tests and an electrocardiogram and will fill out three questionnaires providing information on daily functioning and psychological well-being. This "cross-over" study consists of several parts, including a baseline study and four different treatment regimens. During each part, patients keep a daily log in which they rate their pain, record other procedures they undergo, such as injections and manipulations, and record medication side effects. In the first week of the study, patients remain on their current medications. Any antidepressants or opioids are stopped gradually before starting the drug trials. After the first week, patients go through the following four drug trials in random order: 1. Nortriptyline and inert placebo-Patients take nortriptyline in doses ranging from 25 mg. to 100 mg. and an inert placebo for morphine. (An inert placebo is a dummy pill; it looks like the test drug but has no active ingredient.) 2. MS Contin (morphine) and inert placebo-Patients take MS Contin in doses ranging from 30 mg. to 90 mg. and an inert placebo for nortriptyline. 3. Nortriptyline and MS Contin-Patients take MS Contin and nortriptyline in the same dose ranges as for each drug alone. 4. Active placebo and inactive placebo-Patients take an active placebo-in this case benztropine-and an inert placebo. An active placebo is a drug that does not work for the problem being studied but whose side effects are like those of the test drug-in this case, slight sleepiness or dry mouth. Benztropine is given at one-third the recommended dosage. For each drug regimen, the medication dose is increased gradually over 5 weeks until the maximum tolerated dose is reached. At the end of each regimen, patients are taken off the study drugs over a 12-day tapering period and are off drugs completely for another 2 days. Patients are seen by a doctor or nurse at the 7-week point in each study period. After all the drug trials are finished, patients repeat the questionnaires they filled out at the beginning of the study. Patients and their doctors will be informed of the medications that were effective in each individual's care.
NCT00288769 ↗	Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis	Completed	Soroka University Medical Center	N/A	2006-03-01	Background: Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids . Methods: A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets. Purpose of the research: To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS). Study hypothesis: Treatment with vitamin B12 will reduce the recurrence rate and will diminish the symptomatology of RAS episodes.

Clinical Trial Conditions for MS CONTIN

Condition Name

Condition Name for MS CONTIN
Intervention	Trials
Healthy	2
Pain	1
Precancerous/Nonmalignant Condition	1

Condition MeSH

Condition MeSH for MS CONTIN
Intervention	Trials
Radiculopathy	1
Critical Illness	1
Myelodysplastic Syndromes	1

Clinical Trial Locations for MS CONTIN

Trials by Country

Trials by Country for MS CONTIN
Location	Trials
Canada	4
United States	2
Israel	1
Austria	1

Trials by US State

Trials by US State for MS CONTIN
Location	Trials
Maryland	2

Clinical Trial Progress for MS CONTIN

Clinical Trial Phase

Clinical Trial Phase for MS CONTIN
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for MS CONTIN
Clinical Trial Phase	Trials
Completed	7

Clinical Trial Sponsors for MS CONTIN

Sponsor Name

Sponsor Name for MS CONTIN
Sponsor	Trials
Ranbaxy Inc.	2
National Institute of Nursing Research (NINR)	1
Medical University Innsbruck	1

Sponsor Type

Sponsor Type for MS CONTIN
Sponsor	Trials
Other	3
Industry	2
NIH	2

MS CONTIN Market Analysis and Financial Projection

Last updated: April 28, 2026

What’s the latest on M.S. Contin clinical development and market outlook?

Clinical status: what do current records show for M.S. Contin?

M.S. Contin is the branded extended-release (ER) formulation of morphine sulfate. The label is built around established opioid pharmacology rather than a pipeline of new mechanisms, and most recent “trial updates” in public sources track formulation, bioequivalence, safety monitoring, opioid risk mitigation, and regimen optimization rather than first-in-class efficacy programs.

Clinical development pattern for branded morphine ER (M.S. Contin)

• No new phase 3 registrational program is indicated in mainstream public clinical-trials registries for “M.S. Contin” itself as a novel drug.
• Activity concentrates on:
  • Pharmacokinetics (PK), bioequivalence, and formulation bridging
  • Safety and tolerability in opioid-experienced populations
  • Risk management aligned with REMS-style opioid stewardship practices

Implication for your diligence

• “Update” value is highest when sourced from: formulation-specific submissions, bioequivalence studies, and postmarketing surveillance rather than expectation of late-stage outcome trials.

---

Market analysis: where does M.S. Contin sit in opioid ER demand?

M.S. Contin’s market anchor is its role in the oral ER opioid segment. That segment faces two countervailing forces: long-term opioid demand for chronic pain and tightening prescription controls plus payer restrictions.

Demand drivers that support M.S. Contin

• Established patient base treated with ER morphine for chronic, moderate-to-severe pain.
• Clinician familiarity versus newer ER opioids with less entrenched switching behavior.

Constraints that cap growth

• Regulatory and payer pressure on opioid prescribing.
• Strong switching dynamics toward alternatives with perceived safety profiles, payer-preferred status, or fewer barriers to coverage.
• Continued emphasis on opioid risk mitigation and monitoring, which increases friction for initiating and maintaining ER opioids.

---

Competitive set: what other ER morphine and opioid ER products compete with M.S. Contin?

In practical formulary terms, M.S. Contin competes within:

• ER morphine sulfate products (direct therapeutic substitutes).
• Other ER opioids (therapeutic class substitutes), including ER oxycodone and ER hydromorphone formulations.

Commercial reality for an older branded opioid

• Pricing power depends on whether it stays formulary-preferred versus generic erosion and class-level formulary steering.
• Brand differentiation increasingly comes from coverage and dosing practicality (tablet strength availability and patient-specific titration support) rather than new clinical outcomes.

---

Projection: what is the likely market trajectory for M.S. Contin?

For an established ER opioid brand like M.S. Contin, the most defensible near-to-mid-term projection is typically:

• Mature, slower-growth or contracting branded volumes under pressure from generics and class-level restrictions.
• Stability in total ER morphine class demand driven by persistent chronic pain prevalence, tempered by opioid stewardship.

Base-case projection structure (what to expect in numbers) A credible projection should model three layers:

1. Total ER opioid market trend (growth limited by policy and utilization management).
2. Morphine ER share (competitive switching within ER opioids).
3. Branded share erosion (generic substitution within morphine ER).

Directionally, the branded trajectory is constrained

• Without evidence of a new registrational program or material differentiation, branded share tends to trend downward as coverage and generic penetration expand.

---

Actionable investment and R&D read-through

Where to find the highest-signal updates

For M.S. Contin specifically, the highest-yield “clinical trial updates” you should track in public-facing sources are:

• PK / bioequivalence work tied to manufacturing changes, strength releases, or formulation adjustments.
• Postmarketing safety analyses aligned to opioid risk programs.
• Studies that change dosing conversion protocols between morphine ER and other opioids.

What would change the forecast

The forecast improves only if there is evidence of one of the following:

• A new label expansion that changes eligibility, dosing, or monitoring requirements in a way that payers adopt.
• A meaningful differentiation versus generics (not just strength availability).
• A new evidence package that reduces payer friction (e.g., outcomes tied to lower misuse or reduced discontinuation rates) and gets embedded into coverage policy.

Absent that, the economics stay driven by formulary access, generic penetration, and opioid utilization management.

---

Key Takeaways

• M.S. Contin is an extended-release morphine sulfate brand; public “clinical updates” mostly reflect PK, safety, and risk management rather than new registrational efficacy programs.
• Market growth is structurally capped by opioid prescribing constraints and generic substitution dynamics in ER opioids.
• A realistic projection is mature demand with branded share erosion, unless new label differentiation or payer-embedded evidence shifts coverage behavior.

---

FAQs

1) Is M.S. Contin currently under active phase 3 development for a new indication?

No registrational-style phase 3 development for a new indication is apparent in mainstream public records for M.S. Contin as a novel drug.

2) What types of clinical studies most commonly appear for M.S. Contin?

PK, bioequivalence, formulation bridging, and postmarketing safety monitoring aligned with opioid stewardship.

3) What are the primary market risks for M.S. Contin?

Generic erosion, payer formularies steering away from older branded opioids, and opioid utilization restrictions.

4) What would make the market outlook materially better?

A label change that improves payer acceptance, a differentiation backed by outcomes that affects coverage policy, or a manufacturability event that sustains supply without forcing re-tendering.

5) How should investors model M.S. Contin in financial projections?

Model ER opioid utilization trend, morphine ER share within the ER opioid class, and branded share erosion tied to generic competition and payer rules.

---

References

[1] U.S. Food and Drug Administration. “Drug Trials Snapshots: MS Contin.” FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 2026-04-28).
[2] DailyMed. “MS Contin (morphine sulfate) extended-release tablets.” National Library of Medicine. https://dailymed.nlm.nih.gov/ (accessed 2026-04-28).
[3] FDA. “Opioid Analgesic REMS” and related opioid risk mitigation resources. U.S. Food and Drug Administration. https://www.fda.gov/ (accessed 2026-04-28).
[4] CenterWatch. “Clinical Trials for MS Contin (morphine sulfate).” https://www.centerwatch.com/ (accessed 2026-04-28).